Completed PHASE1 INTERVENTIONAL 2-arm NCT02654522

The Use of a Recombinant DNA-based Hyaluronidase to Dissolve Fixed Amounts of Hyaluronic Acid Dermal Fillers

The Use of a Recombinant DNA-based Hyaluronidase (RDNAH/ Hylenex Recombinant) to Dissolve Fixed Amounts of a Variety of Popular Hyaluronic Acid (HA) Dermal Fillers in Human Subjects.

Sponsor: Steve Yoelin M.D. Medical Associates, Inc.

Conditions Dermal Filler

Interventions Hylenex

Updated 7 times since 2017 Last updated: May 15, 2017 Started: Jan 31, 2016 Primary completion: Feb 29, 2016 Completion: Feb 29, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02654522, this PHASE1 trial focuses on Dermal Filler and remains completed. Sponsored by Steve Yoelin M.D. Medical Associates, Inc., it has been updated 7 times since 2016, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
May 2017 — Jun 2018 [monthly]

Completed PHASE1

Status: Not Yet Recruiting → Completed

▶ Show 2 earlier versions

Feb 2017 — May 2017 [monthly]

Not Yet Recruiting PHASE1
Jan 2017 — Feb 2017 [monthly]

Not Yet Recruiting PHASE1

First recorded

Jan 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Steve Yoelin M.D. Medical Associates, Inc.

Data source: Steve Yoelin M.D. Medical Associates, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.